Brind.
  1. AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.
  2. AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.
  3. AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.
  4. AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.

AbbVie's Humira is losing exclusivity and facing intense competition from Skyrizi and Rinvoq.

2 reports, 1 independent Updated Jul 7
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

AbbVie's Humira is losing exclusivity and facing intense competition from Skyrizi and Rinvoq.

Who's involved

What this event is mainly about
AbbVieHUMIRA

How it developed

Newest first. Tap a step to see who reported it.
  1. Skyrizi and Rinvoq have replaced Humira, marking a significant market shift for AbbVie.1 source
  2. Humira's revenue is being replaced by Skyrizi and Rinvoq amid patent loss.

Keep exploring

Part of

AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition. All 1 developments

Within AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.

The entities involved

Coverage

Newest first; wire copies grouped